Ruth Bader Ginsburg says she’s being treated for recurrence of cancer


Supreme Court of Justice Ruth Bader Ginsburg He said Friday that he is being treated for a recurrence of cancer, but said he “will remain a member of the Court.” The announcement comes days later. she was hospitalized to treat gallstones and an unrelated infection.

According to the Ginsburg statement, she started a course of chemotherapy on May 19. A periodic scan in February followed by a biopsy revealed lesions in her liver. A treatment of immunotherapy It was not successful, but said the chemotherapy course is “giving positive results.”

Ginsburg said his most recent scan on July 7 indicated a significant reduction in liver injury and no new disease. “I am tolerating chemotherapy well and am encouraged by the success of my current treatment,” she said.

She said she will continue biweekly treatment to keep cancer at bay, noting “at all times, I have kept up with the writing of opinions and all the work of the Court.”

In January, Ginsburg said he was “cancer free“She was treated for cancer four times over a span of two decades. She had colorectal cancer in 1999 and pancreatic cancer in 2009.

In August 2018, he underwent a three-week radiation course for a tumor in his pancreas. According to a court statement at the time, the tumor was “definitively” treated and there was no evidence of the disease anywhere else on her body.

In December 2018, he underwent surgery to remove two cancerous nodules from his lung. In January 2019, she lost the oral arguments for the first time in over 25 years.

“The post-surgery evaluation indicates that there is no evidence of disease remaining and that no further treatment is required,” a Supreme Court spokesman said a few weeks later.

Ginsburg’s health is closely watched in Washington, reported Nancy Cordes of CBS News. If she were to leave court during the Trump administration, it would give President Trump the chance to nominate a third judge, and his first chance to replace liberal justice.

Danielle Garrand contributed to this report.

.